MAPK3, one of the identified biomarkers, is expressed in both ECs and SMCs of pulmonary artery, and when activated, it promotes cell proliferation and aggravates the progression of PAH (Tao et al., 2019). Here, MAPK3 is linked to pulmonary arterial hypertension.